An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

In the most recent trading session, Eli Lilly (LLY) closed at $771.75, indicating a -3.45% shift from the previous trading day.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

CNBC host Jim Cramer continues to pound the table on Eli Lilly’s (LLY) stock. The host of the TV show “Mad Money” continues to be a cheerleader for LLY stock, saying repeatedly that the pharmaceutical ...

Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

A weekend focused on women’s health and women’s basketball, all in Eli Lilly’s home state of Indiana? Consider that a layup ...